Information Provided By:
Fly News Breaks for March 4, 2020
MGNX
Mar 4, 2020 | 05:05 EDT
Barclays analyst Peter Lawson initiated coverage of MacroGenics with an Underweight rating and $8 price target.
News For MGNX From the Last 2 Days
MGNX
MGNX
Apr 26, 2024 | 07:26 EDT
B. Riley initiated coverage of MacroGenics with a Buy rating and $25 price target. The analyst views the company's most advanced candidate, vobra duo, as "significantly de-risked" in the ongoing over-enrolled Phase II TAMARACK registration-enabling study, the analyst tells investors in a research note. The firm MacroGenics' fully integrated development and manufacturing capabilities have led to a partnered program portfolio consisting of three FDA-approved medicines and earlier-stage pipeline candidates.
MGNX
Apr 26, 2024 | 07:09 EDT
B. Riley initiated coverage of MacroGenics with a Buy rating and $25 price target.
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.